DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs)

Histone deacetylase inhibitors have been found preclinically to be among the most active agents against DMGs, however, they are clinically ineffective with systemic delivery due to blood brain barrier limitations and toxicity. Using a repurposed device (implantable subcutaneous pump connected with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zacharoulis, Stergios, Szalontay, Luca, CreveCoeur, Travis, Neira, Justin, Higgins, Dominique, Englander, Zachary, Spinazzi, Eleonora, Sethi, Chankrit, Canoll, Peter, Garvin, James, Zylber, Rebecca, Damment, Steve, Zamoryakhin, Dmitry, Maddocks, Alexis, Feldstein, Neil, Bruce, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Drug Delivery/Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165222/
http://dx.doi.org/10.1093/neuonc/noac079.128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165222/
http://dx.doi.org/10.1093/neuonc/noac079.128

Ejemplares similares